Suzetrigine in the Management of Pain Review of the First-in-class Na V1.8 Selective Inhibitor

Introduction. The 2025 FDA approval of suzetrigine (Journavx) ended a 25-year stagnation in analgesic development. This introduced a paradigm shift in pain management. As a first-in-class, highly selective NaV1.8 sodium channel inhibitor, suzetrigine addresses the urgent need for potent, non-opioid options for moderate-to-severe acute pain. It targets channels that are expressed almost exclusively in peripheral nociceptors. Thus, it decouples robust analgesia from systemic risks and addictive potential inherent to traditional opioid therapies. Aim of the study. This review evaluates the status of suzetrigine as of 2026, focusing on its molecular mechanism, clinical efficacy, and safety data from pivotal Phase 3 trials, as well as its broader impact on public health and healthcare economics. Materials and methods. A systematic literature review was conducted using PubMed (up to early 2026). Analysis included structural molecular studies, Phase 2/3 clinical trials (NAVIGATE-1 and -2), and budget impact models regarding the opioid crisis. Conclusions. Suzetrigine represents a significant breakthrough in pain medicine, boasting a 31,000-fold selectivity for NaV1.8, thereby safeguarding the cardiac and central nervous systems. Clinical data demonstrate efficacy comparable to opioid pain therapy, but without respiratory depression, sedation, or physical dependence. Non-opioid mechanisms create measurable, substantial savings by preventing opioid-related adverse events and addiction-related costs. Suzetrigine is seen as a desirable foundation for modern multimodal analgesia, effectively bridging the therapeutic gap between traditional non-opioids and addictive substances.